Search - tctmd.com

Displaying 1 - 14 of 14

Sort: Relevancy | Date

News Conference News ESC 2016

Optimal Approach for BP Lowering Debated Amid New J-Curve Signals in Stable CAD

Todd Neale

September 09, 2016

News Conference News ESC 2016

When Unblinded to Statin Therapy, Patients’ Muscle-Related Adverse Events Shoot Up: ASCOT Analysis

Michael O'Riordan

August 31, 2016

News Conference News ESC 2016

Reversal Agent for Factor Xa Inhibitors Rapidly Reduces Anticoagulant Effects: ANNEXA-4

Todd Neale

August 31, 2016

News Conference News ESC 2016

Ezetimibe Plus Pitavastatin Fails to Lower Risk of CVD Events in ACS Patients: HIJ-PROPER

Michael O'Riordan

August 30, 2016

News Conference News ESC 2016

Platelet Function Testing to Guide Treatment Does Not Benefit Elderly ACS Patients: ANTARCTIC

Todd Neale

August 28, 2016

News Conference News ESC 2016

NOACs as Effective as Warfarin for Reducing Stroke, but Apixaban and Dabigatran May Carry Lower Bleeding Risk: Registry

Michael O'Riordan

August 28, 2016

News Conference News ESC 2016

Focus on LDL Cholesterol Targets With Statin Therapy, New ESC-EAS Cholesterol Guidelines Say

Michael O'Riordan

August 27, 2016

News Conference News ESC 2015

OPTIDUAL: No Clear Need to Lengthen DAPT to 4 Years After DES

Caitlin E. Cox

August 31, 2015

News Conference News ESC 2013

Length of DAPT, Reasons for Discontinuation Have Disparate Effects

Yael L. Maxwell

September 01, 2013

Presentation ESC 2013

Incidence and Impact of Dual Antiplatelet Therapy (DAPT) Cessation on Adverse Events following Percutaneous Coronary Intervention (PCI):Results from the Real-World PARIS Registry

Presenter: 32040|Roxana Mehran

September 01, 2013

Presentation ESC 2012

WOEST: First randomised trial that compares two different regimens with and without aspirin in patients on oral anticoagulant therapy (OAC) undergoing coronary stent placement (PCI)

Presenter: Willem Dewilde

August 28, 2012

News Conference News ESC 2012

WOEST: Clopidogrel Alone Works Best for PCI Patients on Oral Anticoagulants

Yael L. Maxwell

August 28, 2012

News Conference News

RUBY-1: Yet Another Novel Anticoagulant Tested in ACS Patients on Antiplatelets

August 31, 2011

News Conference News

Long-term Antiplatelet Therapy: All Risk, No Benefit

August 30, 2011

Advertisement

Optimal Approach for BP Lowering Debated Amid New J-Curve Signals in Stable CAD

When Unblinded to Statin Therapy, Patients’ Muscle-Related Adverse Events Shoot Up: ASCOT Analysis

Reversal Agent for Factor Xa Inhibitors Rapidly Reduces Anticoagulant Effects: ANNEXA-4

Ezetimibe Plus Pitavastatin Fails to Lower Risk of CVD Events in ACS Patients: HIJ-PROPER

Platelet Function Testing to Guide Treatment Does Not Benefit Elderly ACS Patients: ANTARCTIC

NOACs as Effective as Warfarin for Reducing Stroke, but Apixaban and Dabigatran May Carry Lower Bleeding Risk: Registry

Focus on LDL Cholesterol Targets With Statin Therapy, New ESC-EAS Cholesterol Guidelines Say

OPTIDUAL: No Clear Need to Lengthen DAPT to 4 Years After DES

Length of DAPT, Reasons for Discontinuation Have Disparate Effects

Incidence and Impact of Dual Antiplatelet Therapy (DAPT) Cessation on Adverse Events following Percutaneous Coronary Intervention (PCI):Results from the Real-World PARIS Registry

WOEST: First randomised trial that compares two different regimens with and without aspirin in patients on oral anticoagulant therapy (OAC) undergoing coronary stent placement (PCI)

WOEST: Clopidogrel Alone Works Best for PCI Patients on Oral Anticoagulants

RUBY-1: Yet Another Novel Anticoagulant Tested in ACS Patients on Antiplatelets

Long-term Antiplatelet Therapy: All Risk, No Benefit

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content